Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pancreatic Cancer Treatment Market to Reach $2.9 Billion by 2021

By GBI Research | December 18, 2015

The treatment market for pancreatic cancer is set to grow from its current level of $1.9 billion to an impressive $2.9 billion by 2021, driven primarily by an increased prevalence of the disease, according to business intelligence provider GBI Research.

The company’s latest report* states that this rise, which will occur across the eight major countries of the US, the UK, France, Germany, Italy, Spain, Japan and Canada, will come despite developments in diagnostics and a pipeline of promising new drugs.

Adam Bradbury, Analyst for GBI Research, says that there are six pancreatic cancer drugs expected to gain approval within the forecast period, all of which have demonstrated significant improvement in progression-free survival and/or overall survival in clinical trials.

Bradbury explains: “The six drugs expected to gain approval within the forecast period are Threshold’s TH-302, Merrimack’s Onivyde (in Europe), NewLink Genetic’s HyperAcute Pancreas, Cancer Advances’ G17DT, Immunomedics’ Clivatuzumab Tetraxetan, and Incyte’s Ruxolitinib Phosphate.

“However, these drugs are not expected to significantly impact the market because of their high cost-to-benefit ratio, which will severely limit their sales by 2021.”

GBI Research’s report also states that as pancreatic cancer is a disease with a very poor prognosis, developing drugs with adequate cost-to-benefit ratios is very difficult, and this is reflected in the disease’s high attrition rate of 91% over all three phases of clinical trials.

Bradbury explains: “The poor revenue prospects associated with developing pancreatic cancer therapies will mean many potential investors see it as an unwise investment.

“Despite some improvements in failure rates, further elucidations of mutations and their effects on signalling pathways and disease progression will be required before effective combination therapies can be developed and a significantly lower failure rate achieved.”

The analyst adds that the current pancreatic cancer treatment market is dominated by the generic drug gemcitabine, which is the current standard of care and is widely used for its cost-effectiveness.

Bradbury adds: “Even if priced similarly to gemcitabine, the very poor efficacies of the pipeline drugs in comparison to existing therapies would not offer strong cost-to-benefit ratios.

“For this reason, most of the drugs likely to be approved during the forecast period will be administered as combination therapies, which will prevent companies charging premium prices and limit their market share.”  

*Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 – Strong Late Stage Pipeline Holds Promise for Increasingly Diverse Market Landscape

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE